Citius Oncology Soars 35.06% on Distribution Deal

On July 16, 2025, Citius Oncology's stock surged by 35.06% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Citius Oncology, a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies, has recently expanded its distribution network for its primary asset, LYMPHIR. This expansion includes a new agreement with Cencora, which will serve as a wholesale distributor for LYMPHIR, providing specialty distribution services. This move is expected to enhance the commercial reach and availability of LYMPHIR, a targeted immune therapy approved by the FDA for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

The company's June 2025 financing round has provided it with the necessary capital to execute on its most promising assets, including LYMPHIR. However, the commercialization of LYMPHIR has faced delays, with the earliest launch date now set for late 2025. Despite these challenges, the company's strategic partnerships and regulatory approvals position it well for future growth and success in the oncology market.